Impulse control disorders and dopaminergic drugs [2]

Archives of Neurology

Volumn 63, Issue 2, 2006, Pages 298-299

  Morgan, John C ^a   Iyer, Sanjay S ^b   Sethi, Kapil D ^b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; RISPERIDONE; ROPINIROLE;

AGONIST; CLINICAL RESEARCH; COMPULSION; DOPAMINERGIC ACTIVITY; DRUG MEGADOSE; HUMAN; IMPULSE CONTROL DISORDER; LETTER; LOW DRUG DOSE; PARKINSON DISEASE; PATHOLOGICAL GAMBLING; PRESCRIPTION; PRIORITY JOURNAL; RECEPTOR INTRINSIC ACTIVITY; REWARD; SLEEP DISORDER;

ANTIPARKINSON AGENTS; HUMANS; IMPULSE CONTROL DISORDERS; LEVODOPA; PARKINSON DISEASE;

EID: 32944480345     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.63.2.298-b     Document Type: Letter

References (6)

1. Dodd ML, Klos KJ, Bower JH, Geda YE, Josephs KA, Ahlskog JE. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol. 2005;62:1377-1381.
2. Andén N-E, Carlsson A, Kerstell J, et al. Oral L-dopa treatment of parkinsonism. Acta Med Scand. 1970;187:247-255.
3. Molina JA, Sáinz-Artiga MJ, Fraile A, et al. Pathologic gambling in Parkinson's disease: a behavioral manifestation of pharmacologic treatment? Mov Disord. 2000;15:869-872.
4. Tyne HL, Medley G, Ghadiali E, Steiger MJ. Gambling in Parkinson's disease. Mov Disord. 2004;19(suppl 9):S195.
5. Blum K, Sheridan PJ, Wood RC, et al. The D2 dopamine receptor gene as a determinant of reward deficiency syndrome. J R Soc Med. 1996;89:396-400.
6. Seedat S, Kesler S, Niehaus DJ, Stein DJ. Pathological gambling behaviour: emergence secondary to treatment of Parkinson's disease with dopaminergic agents. Depress Anxiety. 2000;11:185-186.